Information Provided By: 
Fly News Breaks for March 10, 2017
RDUS
Mar 10, 2017 | 11:03 EDT
Canaccord Genuity analyst John Newman says that while the FDA delayed the PDUFA date for abaloparatide to June 30, it did not request any additional data. The analyst still expects abaloparatide to be approved, but admits the risk is now "slightly" higher. The FDA delay is "very surprising" based on the late-stage label discussions regarding abaloparatide, Newman tells investors in a research note. He maintains a Buy rating on Radius with an $85 price target. The stock is down 10%, or $4.27, to $38.84 in morning trading.
News For RDUS From the Last 2 Days
There are no results for your query RDUS
